AGE Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 kov. 2024 @ 21:59):

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States...

Stats
Šios dienos apimtis	3 681.00
Vidutinė apimtis	3 980.00
Rinkos kapitalizacija	27.76M
EPS	$0 ( 2024-03-29 )
Kita pelno data	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Mintz Steven	Sell	0	Common Stock, $0.0001 par value
2024-01-08	Mintz Steven	Sell	63 756	Option to Purchase Common Stock
2023-08-09	Renondin Jean-christophe	Sell	25 821	Option to Purchase Common Stock
2023-04-25	Juvenescence Ltd	Buy	756 429	Warrant to Purchase Common Stock
2023-03-14	Juvenescence Ltd	Sell	16 447 500	Common Stock

INSIDER POWER
-63.36
Last 97 transactions
Buy: 22 648 571 \| Sell: 17 037 050

AgeX Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AgeX Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$142 000
Bruto pelnas:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2023
Pajamos:	$142 000
Bruto pelnas:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2022
Pajamos:	$34 000.00
Bruto pelnas:	$21 000.00 (61.76 %)
EPS:	$-9.89

FY	2021
Pajamos:	$144 000
Bruto pelnas:	$125 000 (86.81 %)
EPS:	$-0.230

Financial Reports:

No articles found.

AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.